Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age ...

It is facing competition in the category from non-steroid drugs like Incyte’s JAK inhibitor Opzelura (ruxolitinib), approved for atopic dermatitis in 2021, although, that requires twice-daily ...

The Prime Minister, Justin Trudeau, today issued the following statement on International Women's Day: "Women in Canada have made transformative progress in shaping our country for the better. Today, ...

As the first quarter of 2025 unfolds, China's innovation landscape reveals compelling patterns through three distinct regional narratives. The eastern tech stronghold of Hangzhou continues its ...

Bank of New York Mellon Corp boosted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 7.5% in the 4th quarter, ...

a JAK inhibitor it sells as Jakafi to treat various haematological cancers and in a topical form as Opzelura for atopic dermatitis and vitiligo. Deuruxolitinib is a deuterated form of ruxolitinib ...